Stealth BioTherapeutics Entered into an Exclusive License Agreement with Pharmanovia to Commercialize Elamipretide for Barth Syndrome
Shots:
- Stealth will receive up front, development, regulatory & commercial milestones along with royalties on net sales of elamipretide in the licensed territories
- Pharmanovia to get an exclusive right to commercialize elamipretide, an investigational mitochondrial protective agent for Barth syndrome in the EU, other EU countries (incl. Iceland, Norway, Switzerland, and the UK) & the MENA
- Elamipretide helps to improve mitochondrial structure & function through its interaction with cardiolipin & has completed P-III development for Barth syndrome. Pharmanovia collaborated with regulatory authorities in the EU & MENA to allow access to a first line of treatment for an ultra-rare genetic cardiac condition
Ref: PRNewswire | Image: Stealth BioTherapeutics
Related News:- Alexion Signs an Option to Co-Develop and Commercialize Agreement with Stealth for Elamipretide
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
